Compare BUUU & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | SLGL |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.2M | 268.9M |
| IPO Year | 2024 | 2016 |
| Metric | BUUU | SLGL |
|---|---|---|
| Price | $28.86 | $83.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 56.4K | 37.8K |
| Earning Date | 05-18-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $347.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.97 | $14.78 |
| 52 Week High | $32.97 | $97.97 |
| Indicator | BUUU | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 50.26 |
| Support Level | $14.04 | $67.53 |
| Resistance Level | N/A | $94.33 |
| Average True Range (ATR) | 2.91 | 5.57 |
| MACD | 0.56 | -0.20 |
| Stochastic Oscillator | 64.29 | 34.36 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.